Recent research advances about vortioxetine: a novel multimodal antidepressant

宗小芬,王高华,胡茂林
DOI: https://doi.org/10.3760/cma.j.cn113661-20210219-00086
2021-01-01
Abstract:Vortioxetine was approved by the US FDA in 2013 and by China Food and Drug Administration in November 2017 for the treatment of major depressive disorder (MDD) in adults. Vortioxetine exerts antidepressant effects by inhibiting 5-HT transporter-mediated 5-HT reuptake and regulating the activity of multiple 5-HT receptors. Vitro and animal studies have shown that, in addition to increasing 5-HT concentrations, vortioxetine elevates dopamine, norepinephrine, acetylcholine, histamine, and glutamate neurotransmission and decreases GABA neurotransmission in some brain areas associated with MDD. Clinical studies indicate that vortioxetine can relieve multidimensional symptoms, improve cognitive functions, and promote the recovery of social function in MDD patients. This article comprehensively reviews vortioxetine for the treatment of depression in aspects of the mechanism of action, clinical efficacy and safety, real-world studies, and clinical application.
What problem does this paper attempt to address?